Investment Rating - The investment rating for the company is "Buy" and is maintained [10] Core Insights - The company is expected to achieve revenue of 14.256 billion HKD and adjusted net profit of 1.530 billion HKD in 2025, representing a year-on-year increase of 21% and 1% respectively [2][7] - The company plans to distribute a dividend of 0.4 HKD per share for the year 2025, resulting in a dividend payout ratio of 234.4% [2][7] - The HNB (Heat-not-Burn) and vaping segments are performing positively, with HNB revenue expected to grow significantly due to new product launches in key markets [11] Revenue Summary - For 2025, the company anticipates a total revenue of 14.256 billion HKD, with a breakdown of 8.243 billion HKD in H2 and 4.046 billion HKD in Q4, showing year-on-year growth rates of 22% and 16% respectively [2][7] - The TOB (Tobacco Operating Business) is projected to contribute 80% of total revenue, with a 22% increase in revenue, while the TOC (Tobacco Operating Company) is expected to grow by 18% [11] Profitability Summary - The gross margin is expected to decline by 3.3 percentage points to 34.1% due to changes in product mix, with increased costs in stock-based compensation and legal services impacting profitability [11] - The company is projected to achieve adjusted net profits of 1.158 billion HKD, 2.020 billion HKD, and 2.770 billion HKD for the years 2026 to 2028, with corresponding PE ratios of 31, 24, and 18 [11] Long-term Outlook - The long-term outlook for HNB and vaping products is positive, with expected compound annual growth rates of 11.5% from 2025 to 2030 [11] - The company is also exploring new business opportunities in medical vaping and other specialized applications, with FDA certification for its manufacturing facility in the U.S. [11]